Sofia Ajeganova

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: LANCET RHEUMATOLOGY. 2024;6(7):e447-e459

Prevalence and target attainment oftraditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries

Bolla E; Semb AG; Kerola AM; Ikdahl E; Petri M; Pons-Estel GJ; Karpouzas GA; Sfikakis PP; Quintana R; Misra DP; Borba EF; Torre IG-DL; Popkova TV; Artim-Esen B; Troldborg A; Fragoso-Loyo H; Ajeganova S; Yazici A; Aroca-Martinez G; Direskeneli H; Ugarte-Gil MF; Mosca M; Goyal M; Svenungsson E; Macieira C; Hoi A; Lerang K; Costedoat-Chalumeau N; Tincani A; Mirrakhimov E; Colman IA; Danza A; Massardo L; Blagojevic J; Yilmaz N; Tegzova D; Yavuz S; Korkmaz C; Hachulla E; Alvarez MJM; Munoz-Louis R; Pantazis N; Tektonidou MG
Article: BMC RHEUMATOLOGY. 2023;7(1):23

Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years

Ajeganova S; Andersson M; Forslind K; Gjertsson I; Nyhall-Wahlin B-M; Svensson B; Hafstrom I
Article: BMC RHEUMATOLOGY. 2022;6(1):88

Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study

Svensson B; Andersson MLE; Gjertsson I; Hafstroem I; Ajeganova S; Forslind K
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2022;14:187-194

Misdiagnosis of Rheumatoid Arthritis in a Long-Term Cohort of Early Arthritis Based on the ACR-1987 Classification Criteria

Agelii ML; Hafstrom I; Svensson B; Ajeganova S; Forslind K; Andersson M; Gjertsson I
Article: ACR OPEN RHEUMATOLOGY. 2021;3(9):642-653

Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6

Sun J; Panda PK; Samal SK; Ahuja R; Ajeganova S; Hafstrom I; Liu A; Frostegard J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(9):1371-1378

Team Rehabilitation in Inflammatory Arthritis Benefits Functional Outcomes Along With Improved Body Composition Associated With Improved Cardiorespiratory Fitness

Ajeganova S; Wornert M; Hafstrom I
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):201

Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events

Ajeganova S; Andersson MLE; Frostegard J; Hafstrom I
Article: LUPUS SCIENCE & MEDICINE. 2021;8(1):e000454

Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years

Ajeganova S; Hafstrom I; Frostegard J
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):32

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms

Frostegard J; Ahmed S; Hafstrom I; Ajeganova S; Rahman M
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2021;13:123-138

Influence of Age and Sex on Disease Course and Treatment in Rheumatoid Arthritis

Nilsson J; Andersson MLE; Hafstrom I; Svensson B; Forslind K; Ajeganova S; Agelii ML; Gjertsson I
Article: LUPUS. 2020;29(8):825-835

Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus

Liu A; Rahman M; Hafstrom I; Ajeganova S; Frostegard J
Article: ALLERGY. 2020;75(4):936-940

Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019

Palomares O; Untersmayr E; Gutermuth J; Agache I; Ajeganova S; Bavbek S; Chan S; Jutel M; Quirce S; Schmid-Grendelmeier P; Schmidt-Weber C; Jose Torres M; Eiwegger T
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20974858-1759720X2097485

Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance

Ajeganova S; De Becker A; Schots R
Article: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000362

Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients

Ajeganova S; Gustafsson T; Lindberg L; Hafstrom I; Frostegard J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(6):431-438

Increased risk of osteoporotic fractures in Swedish patients with rheumatoid arthritis despite early treatment with potent disease-modifying anti-rheumatic drugs: a prospective general population-matched cohort study

Nyhall-Wahlin BM; Ajeganova S; Petersson IF; Andersson MLE
Article: JCI INSIGHT. 2019;4(9):126347

Oxidative hotspots on actin promote skeletal muscle weakness in rheumatoid arthritis

Steinz MM; Persson M; Aresh B; Olsson K; Cheng AJ; Ahlstrand E; Lilja M; Lundberg TR; Rullman E; Moller KA; Sandor K; Ajeganova S; Yamada T; Beard N; Karlsson BCG; Tavi P; Kenne E; Svensson CI; Rassier DE; Karlsson R; Friedman R; Gustafsson T; Lanner JT
Article: ARTHRITIS RESEARCH & THERAPY. 2019;21(1):45

Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort

Hafstrom I; Ajeganova S; Forslind K; Svensson B
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2019;11:207-217

A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance

Hafstrom I; Ajeganova S; Andersson MLE; Bala S-V; Bergman S; Bremander A; Forslind K; Malm K; Svensson B
Article: LUPUS. 2018;27(10):1670-1678

Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus

Frostegard J; Hellstrom C; Nilsson P; Frostegard AG; Ajeganova S
Article: CLINICAL RHEUMATOLOGY. 2018;37(7):1825-1834

Variation in pain related to systemic lupus erythematosus (SLE): a 7-year follow-up study

Waldheim E; Ajeganova S; Bergman S; Frostegard J; Welin E
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018;36(3):428-433

Association between dietary and metabolic factors and IgM antibodies to phosphorylcholine and malondialdehyde in patients with systemic lupus erythematosus and population-based matched controls

Lourdudoss C; Ajeganova S; Frostegard J
Article: ATHEROSCLEROSIS. 2018;268:36-48

IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors

Sun J; Lundstrom SL; Zhang B; Zubarev RA; Steuer J; Gillgren P; Rahman M; Ajeganova S; Liu A; Frostegard J
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):115

The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical

Boeters DM; Mangnus L; Ajeganova S; Lindqvist E; Svensson B; Toes REM; Trouw LA; Huizinga TWJ; Berenbaum F; Morel J; Rantapaa-Dahlqvist S; van der Helm-van Mil AHM
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(4):716-720

Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present

Derksen VFAM; Ajeganova S; Trouw LA; van der Helm-van Mil AHM; Hafstrom I; Huizinga TWJ; Toes REM; Svensson B; van der Woude D
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):44

Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

Ajeganova S; Tesfa D; Hgglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):112-118

The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor

Ajeganova S; van Steenbergen HW; Verheul MK; Forslind K; Hafstrom I; Toes REM; Huizinga TWJ; Svensson B; Trouw LA; van der Helm-van Mil AHM
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):285

Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study

van Wesemael TJ; Ajeganova S; Humphreys J; Terao C; Muhammad A; Symmons DPM; MacGregor AJ; Hafstrom I; Trouw LA; van der Helm-van Mil AHM; Huizinga TWJ; Mimori T; Toes REM; Matsuda F; Svensson B; Verstappen SMM; van der Woude D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(11):1924-1932

Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts

Ajeganova S; Humphreys JH; Verheul MK; van Steenbergen HW; van Nies JAB; Hafstrom I; Svensson B; Huizinga TWJ; Trouw LA; Verstappen SMM; van der Helm-van Mil AHM
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(6):448-455

Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study

Svensson B; Andersson MLE; Forslind K; Ajeganova S; Hafstrom I
Article: JOURNAL OF REHABILITATION MEDICINE. 2016;48(8):711-718

A FOUR-WEEK TEAM-REHABILITATION PROGRAMME IN A WARM CLIMATE DECREASES DISABILITY AND IMPROVES HEALTH AND BODY FUNCTION FOR UP TO ONE YEAR: A PROSPECTIVE STUDY IN SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES

Ajeganova S; Wornert M; Hafstrom I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(5):867-873

Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms

Ajeganova S; van Steenbergen HW; van Nies JAB; Burgers LE; Huizinga TWJ; van der Helm-van Mil AHM
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):84

Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study

Ajeganova S; Gustafsson T; Jogestrand T; Frostegard J; Hafstrom I
Article: BMJ OPEN. 2014;4(4):e004259

Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial

Ajeganova S; Svensson B; Hafstrom I
Article: JOURNAL OF RHEUMATOLOGY. 2013;40(12):1958-1966

Disease Factors in Early Rheumatoid Arthritis Are Associated with Differential Risks for Cardiovascular Events and Mortality Depending on Age at Onset: A 10-year Observational Cohort Study

Ajeganova S; Andersson MLE; Frostegard J; Hafstrom I
Article: ARTHRITIS CARE & RESEARCH. 2013;65(1):78-87

Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset

Ajeganova S; Andersson ML; Hafstrom I
Article: JOURNAL OF RHEUMATOLOGY. 2012;39(6):1146-1154

Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis - An Inception Cohort Study

Ajeganova S; de Faire U; Jogestrand T; Frostegard J; Hafstroem I
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2011;29(6):942-950

Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: a one-year study

Ajeganova S; Fiskesund R; de Faire U; Hafstrom I; Frostegard J
Article: RHEUMATOLOGY. 2011;50(10):1785-1793

Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset-a prospective cohort study

Ajeganova S; Ehrnfelt C; Alizadeh R; Rohani M; Jogestrand T; Hafstrom I; Frostegard J
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(8):2209-2214

Late-Onset Neutropenia Following Rituximab Therapy in Rheumatic Diseases: Association With B Lymphocyte Depletion and Infections

Tesfa D; Ajeganova S; Hagglund H; Sander B; Fadeel B; Hafstrom I; Palmblad J
Visa fler

Alla övriga publikationer

Letter: ARTHRITIS & RHEUMATOLOGY. 2018;70(12):2096-2097

Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al

Derksen VFAM; Westerlind H; Saevarsdottir S; Ajeganova S; Trouw LA; Huizinga TWJ; van der Helm-van Mil AHM; Knevel R; van der Woude D
Review: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2017;9(10):249-262

Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations

Ajeganova S; Huizinga T
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(7):e17

Disease-modifying treatment in rheumatoid arthritis: treat early and do not forget to try to taper and stop

Ajeganova S; van der Helm-van Mil AHM
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(4):e14-EU5

Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis

Ajeganova S; Svensson B; Huizinga TWJ; van der Helm-van Mil AHM; van Steenbergen HW
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(1):e3

The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis

van Steenbergen HW; Ajeganova S; Forslind K; Svensson B; van der Helm-van Mil AHM
Editorial comment: NATURE REVIEWS RHEUMATOLOGY. 2015;11(1):8-9

Seronegative and seropositive RA: alike but different?

Ajeganova S; Huizinga TWJ
Letter: JOURNAL OF RHEUMATOLOGY. 2013;40(3):337-338

Prognosis Factors for Cardiovascular Events in Patients with Rheumatoid Arthritis: Multivariate Analysis Is Indispensable Reply

Ajeganova S; Hafstrom I
Thesis / dissertation: 2012

Addressing cardiovascular risk factors and therapy effects in rheumatoid arthritis : implications for atherosclerosis and cardiovascular disease

Ajeganova, Sofia
Letter: ARTHRITIS & RHEUMATOLOGY. 2012;64(2):597

Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al Reply

Tesfa D; Ajeganova S; Hafstrom I; Palmblad J

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2013

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI